About doxorubici n hydrochlo
Anthracycline antineoplastic antibiotic
Used for
- Treats several cancers, including breast cancer, lymphomas, and leukemias.
Usual adult dose
Varies by cancer and treatment plan; commonly 40–75 mg/m² intravenously every 3–4 weeks.
Usual dose in children
Varies by cancer and treatment plan; specialist-calculated doses are given intravenously, often in treatment cycles.
Common side effects
- Low blood counts, increasing infection or bleeding risk
- Nausea, vomiting, mouth sores, and hair loss
- Heart muscle damage, sometimes causing heart failure
- Red or orange urine for a short time
Important warnings
- Can cause serious heart damage; risk increases with cumulative exposure.
- Can severely suppress blood-cell production; blood tests are required.
- Must be given into a vein; leakage can cause severe tissue injury.
- Can harm an unborn baby and may affect fertility.
Pregnancy
May harm the fetus. Avoid during pregnancy unless a specialist determines treatment is essential.
Breastfeeding
Breastfeeding is not recommended during treatment because the medicine may harm the infant.
Interactions
- Other medicines that damage the heart can increase heart risks.
- Live vaccines may cause infection during treatment-related immune suppression.
- Some chemotherapy medicines can increase toxicity or alter doxorubicin exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.